DrugPatentWatch Database Preview
Tesamorelin acetate - Generic Drug Details
Join the DrugPatentWatch Referral Program Get access to a free drug patent landscape report or a free one-month subscription
What are the generic drug sources for tesamorelin acetate and what is the scope of patent protection?
Tesamorelin acetate
is the generic ingredient in one branded drug marketed by Theratechnologies and is included in one NDA. There are five patents protecting this compound. Additional information is available in the individual branded drug profile pages.Tesamorelin acetate has forty-four patent family members in sixteen countries.
One supplier is listed for this compound.
Summary for tesamorelin acetate
| International Patents: | 44 |
| US Patents: | 5 |
| Tradenames: | 1 |
| Applicants: | 1 |
| NDAs: | 1 |
| Suppliers / Packagers: | 1 |
| Bulk Api Vendors: | 1 |
| DailyMed Link: | tesamorelin acetate at DailyMed |
Synonyms for tesamorelin acetate
| (3E)-Hex-3-enoylsomatoliberin (human) acetate (salt) |
| 901758-09-6 |
| LGW5H38VE3 |
| Tesamorelin acetate [USAN] |
| TH9507 |
| UNII-LGW5H38VE3 |
US Patents and Regulatory Information for tesamorelin acetate
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Exclusivity Expiration |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Theratechnologies | EGRIFTA | tesamorelin acetate | POWDER;SUBCUTANEOUS | 022505-002 | Nov 29, 2011 | RX | Yes | Yes | Start Trial | Start Trial | Start Trial | ||||
| Theratechnologies | EGRIFTA | tesamorelin acetate | POWDER;SUBCUTANEOUS | 022505-002 | Nov 29, 2011 | RX | Yes | Yes | Start Trial | Start Trial | Y | Y | Start Trial | ||
| Theratechnologies | EGRIFTA | tesamorelin acetate | POWDER;SUBCUTANEOUS | 022505-002 | Nov 29, 2011 | RX | Yes | Yes | Start Trial | Start Trial | Start Trial | ||||
| Theratechnologies | EGRIFTA | tesamorelin acetate | POWDER;SUBCUTANEOUS | 022505-001 | Nov 10, 2010 | RX | Yes | Yes | Start Trial | Start Trial | Start Trial | ||||
| Theratechnologies | EGRIFTA | tesamorelin acetate | POWDER;SUBCUTANEOUS | 022505-002 | Nov 29, 2011 | RX | Yes | Yes | Start Trial | Start Trial | Start Trial | ||||
| Theratechnologies | EGRIFTA | tesamorelin acetate | POWDER;SUBCUTANEOUS | 022505-001 | Nov 10, 2010 | RX | Yes | Yes | Start Trial | Start Trial | Start Trial | ||||
| >Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Exclusivity Expiration |
Expired US Patents for tesamorelin acetate
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | Patent No. | Patent Expiration |
|---|---|---|---|---|---|---|---|
| Theratechnologies | EGRIFTA | tesamorelin acetate | POWDER;SUBCUTANEOUS | 022505-001 | Nov 10, 2010 | Start Trial | Start Trial |
| Theratechnologies | EGRIFTA | tesamorelin acetate | POWDER;SUBCUTANEOUS | 022505-002 | Nov 29, 2011 | Start Trial | Start Trial |
| >Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >Patent No. | >Patent Expiration |
International Patents for tesamorelin acetate
| Country | Patent Number | Estimated Expiration |
|---|---|---|
| Canada | 2527039 | Start Trial |
| European Patent Office | 0828758 | Start Trial |
| Canada | 2485472 | Start Trial |
| Japan | H11505807 | Start Trial |
| Brazil | 9913515 | Start Trial |
| World Intellectual Property Organization (WIPO) | 2004105789 | Start Trial |
| >Country | >Patent Number | >Estimated Expiration |
